Detect Early. Save Lives.

Early lung cancer detection with a simple blood test. Our CIZ1B biomarker test is a non-invasive, cost effective breakthrough for detecting lung cancer at its earliest stages.

Partner with Cizzle Biotechnology PLC

Partner with Cizzle Biotechnology Advancing Early Cancer Detection Together

Guided by a mission to improve lung cancer survival, we aim to reshape the future of lung cancer diagnostics.

Strategic Partnerships & Licensing for Greater Impact:

Through strategic global partnerships, we are fast-tracking the deployment of our innovative blood test. We consider this to be the surest route to achieving our goal of earlier diagnosis, improved patient outcomes, and wider access — ultimately saving lives.

Unlocking Global Potential:

Our strategic licensing model enables rapid market deployment, bringing our innovative solution to healthcare providers globally.

We have already secured our first strategic partner in North America and will be expanding globally through additional licensing and collaborations.

Interested in partnering with us? Get in touch to explore collaboration opportunities.

Why Partner with Us? Transforming the Diagnostic Landscape

Cizzle is pioneering a new era in early lung cancer diagnosis with its patent-protected CIZ1B biomarker technology. Our diagnostic solution is non-invasive, cost-effective, and scalable, enabling earlier detection, better patient outcomes, and significant competitive advantages for our partners.

Innovation That Sets New Standards

Clinical Validation

Scalable Partnerships Model:

Partner with Us to Transform Cancer Detection

We are actively seeking forward-thinking partners in healthcare, biotechnology, and investment to scale our impact and revolutionise early lung cancer detection.

Beyond licensing, we collaborate across the healthcare ecosystem—from providers to insurers—to expand access, accelerate adoption, and improve patient outcomes. If you share our vision for a future where lung cancer is detected earlier and treated more effectively, let’s explore how we can work together.

Current Collaboration

Partnerships drive innovation and accelerate global adoption of our lung cancer diagnostic technology.

Partner with us.